Cargando…
Lumasiran for primary hyperoxaluria type 1: What we have learned?
Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive genetic disorder caused by mutations in the AGXT gene. The hepatic peroxisomal enzyme alanine glyoxylate aminotransferase (AGT) defects encoded by the AGXT gene increase oxalate production, resulting in nephrocalcinosis, nephrolithiasi...
Autores principales: | Gang, Xuan, Liu, Fei, Mao, Jianhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871624/ https://www.ncbi.nlm.nih.gov/pubmed/36704142 http://dx.doi.org/10.3389/fped.2022.1052625 |
Ejemplares similares
-
Infantile Primary Hyperoxaluria Type 1 Treated With Lumasiran in Twin Males
por: Aldabek, Khaled, et al.
Publicado: (2022) -
Case Report: Sustained Efficacy of Lumasiran at 18 Months in Primary Hyperoxaluria Type 1
por: Chiodini, Benedetta, et al.
Publicado: (2022) -
Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside
por: D’Ambrosio, Viola, et al.
Publicado: (2022) -
Lumasiran: a potential therapy for the management of primary hyperoxaluria type 1? An editorial
por: Ghani, Sundus A., et al.
Publicado: (2023) -
Lessons for the clinical nephrologist: lumasiran as the future cornerstone treatment for patients with primary hyperoxaluria type 1?
por: Gillion, Valentine, et al.
Publicado: (2022)